Thrivent Financial for Lutherans Acquires Shares of 64,040 Guardant Health, Inc. $GH

Thrivent Financial for Lutherans acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 64,040 shares of the company’s stock, valued at approximately $6,541,000.

Other hedge funds also recently modified their holdings of the company. V Square Quantitative Management LLC acquired a new position in shares of Guardant Health during the 4th quarter worth $27,000. Chesapeake Asset Management LLC acquired a new position in shares of Guardant Health during the 4th quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new position in shares of Guardant Health during the 4th quarter worth $31,000. First Pacific Financial acquired a new position in shares of Guardant Health during the 4th quarter worth $43,000. Finally, Optiver Holding B.V. increased its stake in shares of Guardant Health by 153.5% during the 3rd quarter. Optiver Holding B.V. now owns 768 shares of the company’s stock worth $48,000 after purchasing an additional 465 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Guardant Health Trading Up 17.1%

NASDAQ:GH opened at $114.97 on Thursday. Guardant Health, Inc. has a 1 year low of $36.36 and a 1 year high of $120.74. The firm’s fifty day simple moving average is $89.98 and its 200 day simple moving average is $98.62. The firm has a market capitalization of $15.25 billion, a PE ratio of -33.91 and a beta of 1.48.

Guardant Health (NASDAQ:GH) last posted its earnings results on Thursday, February 19th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to analyst estimates of $269.74 million. During the same quarter in the previous year, the firm earned ($0.62) EPS. The company’s revenue was up 39.4% compared to the same quarter last year. As a group, analysts anticipate that Guardant Health, Inc. will post -2.87 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently commented on GH. Citigroup increased their price target on shares of Guardant Health from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Barclays increased their price target on shares of Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Guggenheim increased their price target on shares of Guardant Health from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. BTIG Research increased their price target on shares of Guardant Health from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Finally, Canaccord Genuity Group increased their price target on shares of Guardant Health from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Friday, February 20th. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Guardant Health has a consensus rating of “Moderate Buy” and a consensus price target of $129.42.

Insider Buying and Selling

In other Guardant Health news, Director Medina Manuel Hidalgo sold 1,300 shares of the firm’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $91.54, for a total value of $119,002.00. Following the sale, the director directly owned 1,193 shares in the company, valued at $109,207.22. This trade represents a 52.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Terilyn J. Monroe sold 3,832 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $92.68, for a total transaction of $355,149.76. Following the completion of the sale, the insider owned 20,990 shares in the company, valued at $1,945,353.20. This represents a 15.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 58,712 shares of company stock worth $5,802,899. 5.60% of the stock is currently owned by corporate insiders.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.